Do you remember back in Early 2007 when DNDN was trading for about $4 and then over night gapped up to about $18? I remember it very clearly because some of my friends made hundreds of thousands that day.

DNDN gapped that day because because an FDA advisory commitee had reviewed their drug and found it adequate. Here is an excerpt from the press release:

“the U.S. Food and Drug Administration’s (FDA) Office of Cellular, Tissue and Gene Therapies Advisory Committee recommended to the FDA that there is substantial evidence of efficacy and safety of PROVENGE (sipuleucel-T) for the treatment of patients with asymptomatic, metastatic, androgen-independent (also known as hormone refractory) prostate cancer. The FDA will review the advisory committee’s recommendations.”

DNDN’s drug wasn’t even cleared yet.

Fast foward to 2009 and GTCB’s anti-clotting drug Atyn has been given positive comments by the FDA staff reviewers. A final decesion could be made this Friday. GTCB is still trading at under $1.00 although it has made quite a substantial gain already.

Playing bio tech companies can be very dangerous but rewarding too. I believe GTCB’s current price still makes it very attractive as the upside potential could be 200-300% from these levels.